Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2526]

Immune response prognostic for prostate cancer survival, recurrence and response to radiation therapy

Immune response prognostic for prostate cancer survival, recurrence and response to radiation therapy

Pioneering ‘precision’ radiotherapy boosts prostate cancer survival

Pioneering ‘precision’ radiotherapy boosts prostate cancer survival

Erectile tissue-sparing radiation technique offers no additional preservation of sexual function for men with prostate cancer

Erectile tissue-sparing radiation technique offers no additional preservation of sexual function for men with...

FDA approves first biosimilar for the treatment of cancer

FDA approves first biosimilar for the treatment of cancer

Chronic cell death promotes liver cancer

Chronic cell death promotes liver cancer

ESMO 2017: Combined lenvatinib and pembrolizumab produces notable response rates in advanced renal carcinoma

ESMO 2017: Combined lenvatinib and pembrolizumab produces notable response rates in advanced renal carcinoma

ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer

ESMO 2017: Mature results favour pembrolizumab as second-line treatment for bladder cancer

ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer

ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer

Liver cancer patients can start with lower dose of chemotherapy and live just as long

Liver cancer patients can start with lower dose of chemotherapy and live just as long

ESMO 2017: Patients with high risk prostate cancer may benefit “equally” from two new treatments

ESMO 2017: Patients with high risk prostate cancer may benefit “equally” from two new treatments

More from ecancer